Dive Brief:

简报：

SciNeuro Pharmaceuticals, a startup founded in 2020, said Thursday it has

科学神经制药公司（SciNeuro Pharmaceuticals），一家成立于2020年的初创公司，周四表示

raised $53 million

筹集了5300万美元

to support its work developing drugs for nerve-destroying disorders.

以支持其开发治疗神经破坏性疾病的药物的工作。

Arch Venture Partners and China-based LAV led the equity financing, which also received contributions from new and existing investors. The proceeds, according to SciNeuro, will go toward advancing the company’s slate of drug programs, which target a “range of disease pathways” tied to illnesses like Alzheimer’s and Parkinson’s..

Arch Venture Partners和中国LAV领投了这笔股权融资，新老投资者也参与了投资。SciNeuro表示，所得款项将用于推进公司的药物项目，这些项目针对与阿尔茨海默病和帕金森病等疾病相关的“多种疾病通路”。

Alongside the financing, SciNeuro announced the appointment of Hogan Wan as chief financial officer. Wan brings more than a decade of experience in biopharma corporate finance and investment banking, and most recently served as head of investor relations and strategy at Ascentage Pharma, where he led the process for the cancer drugmaker’s .

伴随融资，SciNeuro 宣布任命万昊为首席财务官。万昊在生物制药公司财务和投资银行领域拥有十多年的经验，最近曾担任亚盛医药的投资者关系与战略负责人，领导了这家抗癌药物制造商的相关进程。

initial public offering

首次公开募股

.

。

Dive Insight:

深度洞察：

Arch is one of the most prolific backers of young biotechnology companies. A BioPharma Dive database shows it has participated in

Arch 是最积极支持年轻生物技术公司的投资机构之一。BioPharma Dive 数据库显示，它已参与了

at least 74 funding rounds

至少74轮融资

since 2022, including 13 in 2025. And that activity is likely to continue, as Arch last year

自 2022 年以来，包括 2025 年的 13 次。而这项活动可能会继续，因为 Arch 去年

raised another $3 billion

筹集了额外的30亿美元

to pump into startups.

注入初创企业。

SciNeuro represents the latest in a string of Arch investments directed at the nervous system, a notoriously challenging area of drug development with

SciNeuro代表了Arch在神经系统领域的一系列最新投资，这一领域以药物开发的高难度著称。

even lower rates

更低的利率

of success than others. Arch contributed to

比其他人更成功。Arch为此做出了贡献

a $115 million Series C round

1.15亿美元的C轮融资

for Aspen Neuroscience that completed last month, as well as

上个月完成的Aspen Neuroscience融资，以及

a $200 million haul

2亿美元的收入

for Tenvie Therapeutics in January.

为Tenvie Therapeutics公司一月份。

At SciNeuro, scientists are trying to create innovative therapies directed at proteins like beta amyloid and LRRK2, the latter of which is strongly linked to Parkinson’s. The company is also supported by a recent $5 million, non-dilutive research grant from The Michael J. Fox Foundation for Parkinson's Research..

在 SciNeuro，科学家们正试图针对β淀粉样蛋白和 LRRK2 等蛋白质开发创新疗法，后者与帕金森病有很强的关联。该公司还获得了迈克尔·J·福克斯帕金森研究基金会最近提供的 500 万美元的非稀释性研究资助。

The equity financing unveiled Thursday “represents a significant milestone for SciNeuro and demonstrates our commitment to advancing the science behind neurodegenerative disease treatments,” said Min Li, the company’s founder and CEO.

周四公布的股权融资“代表了赛神神经科学的一个重要里程碑，表明了我们对推进神经退行性疾病治疗背后的科学的承诺，”公司创始人兼首席执行官李敏说。